Fig. 1From: Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patientsAnti-HIV activity of albuvirtide and LPV/r. a Mean change of plasma HIV RNA over time by dose group. b Percentage of patients with viral load <50, 200 and 400 copies/ml on Day 47Back to article page